Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody

Shuai Yue; Zhirong Li; Yao Lin; Yang Yang; Mengqi Yuan; Zhiwei Pan; Li Hu; Leiqiong Gao; Jing Zhou; Jianfang Tang; Yifei Wang; Qin Tian; Yaxing Hao; Juan Wang; Qizhao Huang; Lifan Xu; Bo Zhu; Pinghuang Liu; Kai Deng; Li Wang; Lilin Ye; Xiangyu Chen

doi:10.3389/fimmu.2021.751584

Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody

Shuai Yue, Zhirong Li, Yao Lin, Yang Yang, Mengqi Yuan, Zhiwei Pan, Li Hu, Leiqiong Gao, Jing Zhou, Jianfang Tang, Yifei Wang, Qin Tian, Yaxing Hao, Juan Wang, Qizhao Huang, Lifan Xu, Bo Zhu, Pinghuang Liu, Kai Deng^*, Li Wang^*Lilin Ye^*, Xiangyu Chen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel coronavirus disease (COVID-19). Though vaccines and neutralizing monoclonal antibodies (mAbs) have been developed to fight COVID-19 in the past year, one major concern is the emergence of SARS-CoV-2 variants of concern (VOCs). Indeed, SARS-CoV-2 VOCs such as B.1.1.7 (UK), B.1.351 (South Africa), P.1 (Brazil), and B.1.617.1 (India) now dominate the pandemic. Herein, we found that binding activity and neutralizing capacity of sera collected from convalescent patients in early 2020 for SARS-CoV-2 VOCs, but not non-VOC variants, were severely blunted. Furthermore, we observed evasion of SARS-CoV-2 VOCs from a VH3-30 mAb 32D4, which was proved to exhibit highly potential neutralization against wild-type (WT) SARS-CoV-2. Thus, these results indicated that SARS-CoV-2 VOCs might be able to spread in convalescent patients and even harbor resistance to medical countermeasures. New interventions against these SARS-CoV-2 VOCs are urgently needed.

Original language	English
Article number	751584
Journal	Frontiers in Immunology
Volume	12
DOIs	https://doi.org/10.3389/fimmu.2021.751584
Publication status	Published - 23 Sept 2021
Externally published	Yes

Keywords

COVID-19
SARS-CoV-2 variants
antibody response
convalescent sera
neutralizing mAb

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3389/fimmu.2021.751584

Cite this

Yue, S., Li, Z., Lin, Y., Yang, Y., Yuan, M., Pan, Z., Hu, L., Gao, L., Zhou, J., Tang, J., Wang, Y., Tian, Q., Hao, Y., Wang, J., Huang, Q., Xu, L., Zhu, B., Liu, P., Deng, K., ... Chen, X. (2021). Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody. Frontiers in Immunology, 12, Article 751584. https://doi.org/10.3389/fimmu.2021.751584

@article{f9eb47ed243b4e518f872e582a15a5e9,

title = "Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody",

abstract = "The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel coronavirus disease (COVID-19). Though vaccines and neutralizing monoclonal antibodies (mAbs) have been developed to fight COVID-19 in the past year, one major concern is the emergence of SARS-CoV-2 variants of concern (VOCs). Indeed, SARS-CoV-2 VOCs such as B.1.1.7 (UK), B.1.351 (South Africa), P.1 (Brazil), and B.1.617.1 (India) now dominate the pandemic. Herein, we found that binding activity and neutralizing capacity of sera collected from convalescent patients in early 2020 for SARS-CoV-2 VOCs, but not non-VOC variants, were severely blunted. Furthermore, we observed evasion of SARS-CoV-2 VOCs from a VH3-30 mAb 32D4, which was proved to exhibit highly potential neutralization against wild-type (WT) SARS-CoV-2. Thus, these results indicated that SARS-CoV-2 VOCs might be able to spread in convalescent patients and even harbor resistance to medical countermeasures. New interventions against these SARS-CoV-2 VOCs are urgently needed.",

keywords = "COVID-19, SARS-CoV-2 variants, antibody response, convalescent sera, neutralizing mAb",

author = "Shuai Yue and Zhirong Li and Yao Lin and Yang Yang and Mengqi Yuan and Zhiwei Pan and Li Hu and Leiqiong Gao and Jing Zhou and Jianfang Tang and Yifei Wang and Qin Tian and Yaxing Hao and Juan Wang and Qizhao Huang and Lifan Xu and Bo Zhu and Pinghuang Liu and Kai Deng and Li Wang and Lilin Ye and Xiangyu Chen",

note = "Publisher Copyright: {\textcopyright} Copyright {\textcopyright} 2021 Yue, Li, Lin, Yang, Yuan, Pan, Hu, Gao, Zhou, Tang, Wang, Tian, Hao, Wang, Huang, Xu, Zhu, Liu, Deng, Wang, Ye and Chen.",

year = "2021",

month = sep,

day = "23",

doi = "10.3389/fimmu.2021.751584",

language = "English",

volume = "12",

journal = "Frontiers in Immunology",

issn = "1664-3224",

publisher = "Frontiers Media SA",

}

Yue, S, Li, Z, Lin, Y, Yang, Y, Yuan, M, Pan, Z, Hu, L, Gao, L, Zhou, J, Tang, J, Wang, Y, Tian, Q, Hao, Y, Wang, J, Huang, Q, Xu, L, Zhu, B, Liu, P, Deng, K, Wang, L, Ye, L & Chen, X 2021, 'Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody', Frontiers in Immunology, vol. 12, 751584. https://doi.org/10.3389/fimmu.2021.751584

TY - JOUR

T1 - Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody

AU - Yue, Shuai

AU - Li, Zhirong

AU - Lin, Yao

AU - Yang, Yang

AU - Yuan, Mengqi

AU - Pan, Zhiwei

AU - Hu, Li

AU - Gao, Leiqiong

AU - Zhou, Jing

AU - Tang, Jianfang

AU - Wang, Yifei

AU - Tian, Qin

AU - Hao, Yaxing

AU - Wang, Juan

AU - Huang, Qizhao

AU - Xu, Lifan

AU - Zhu, Bo

AU - Liu, Pinghuang

AU - Deng, Kai

AU - Wang, Li

AU - Ye, Lilin

AU - Chen, Xiangyu

PY - 2021/9/23

Y1 - 2021/9/23

N2 - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel coronavirus disease (COVID-19). Though vaccines and neutralizing monoclonal antibodies (mAbs) have been developed to fight COVID-19 in the past year, one major concern is the emergence of SARS-CoV-2 variants of concern (VOCs). Indeed, SARS-CoV-2 VOCs such as B.1.1.7 (UK), B.1.351 (South Africa), P.1 (Brazil), and B.1.617.1 (India) now dominate the pandemic. Herein, we found that binding activity and neutralizing capacity of sera collected from convalescent patients in early 2020 for SARS-CoV-2 VOCs, but not non-VOC variants, were severely blunted. Furthermore, we observed evasion of SARS-CoV-2 VOCs from a VH3-30 mAb 32D4, which was proved to exhibit highly potential neutralization against wild-type (WT) SARS-CoV-2. Thus, these results indicated that SARS-CoV-2 VOCs might be able to spread in convalescent patients and even harbor resistance to medical countermeasures. New interventions against these SARS-CoV-2 VOCs are urgently needed.

AB - The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic of novel coronavirus disease (COVID-19). Though vaccines and neutralizing monoclonal antibodies (mAbs) have been developed to fight COVID-19 in the past year, one major concern is the emergence of SARS-CoV-2 variants of concern (VOCs). Indeed, SARS-CoV-2 VOCs such as B.1.1.7 (UK), B.1.351 (South Africa), P.1 (Brazil), and B.1.617.1 (India) now dominate the pandemic. Herein, we found that binding activity and neutralizing capacity of sera collected from convalescent patients in early 2020 for SARS-CoV-2 VOCs, but not non-VOC variants, were severely blunted. Furthermore, we observed evasion of SARS-CoV-2 VOCs from a VH3-30 mAb 32D4, which was proved to exhibit highly potential neutralization against wild-type (WT) SARS-CoV-2. Thus, these results indicated that SARS-CoV-2 VOCs might be able to spread in convalescent patients and even harbor resistance to medical countermeasures. New interventions against these SARS-CoV-2 VOCs are urgently needed.

KW - COVID-19

KW - SARS-CoV-2 variants

KW - antibody response

KW - convalescent sera

KW - neutralizing mAb

UR - http://www.scopus.com/inward/record.url?scp=85116539046&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2021.751584

DO - 10.3389/fimmu.2021.751584

M3 - Article

C2 - 34630430

AN - SCOPUS:85116539046

SN - 1664-3224

VL - 12

JO - Frontiers in Immunology

JF - Frontiers in Immunology

M1 - 751584

ER -

Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this